Pfizer vaccine associated with lower risk of SARS-CoV-2 infection and hospitalization in middle-aged adults

By | December 24, 2021
New findings suggest that the Pfizer-BioNTech mRNA COVID-19 vaccines provide extra protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) than AstraZeneca.